CIK 0000907654 · Non-accelerated filer<br>Smaller reporting company
Oruka Therapeutics, Inc.
Sign in to watch- Ticker
- ORKA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 363855489
- Phone
- 650-606-7910
- Business address
- 855 OAK GROVE AVE., SUITE 100, MENLO PARK, CA, 94025
- Former names
- ARCA biopharma, Inc., NUVELO INC, HYSEQ INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $20,653,308
- in 17 filings, $20.2M under 10b5-1 plans
Net −$20,653,308. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Klein Lawrence Otto −$11.6M Chief Executive Officer sold 12% of stake
- Agarwal Arjun −$2.8M Senior Vice President, Finance sold 68% of stake
- Goncalves Joana −$2.0M Chief Medical Officer sold 41% of stake
- BALL KRISTINE M −$1.9M Director sold 100% of stake
- Quinlan Paul T −$1.7M General Counsel sold 40% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-12 | Agarwal Arjun Senior Vice President, Finance | Sale 10b5-1 | −1,859 | $68.34 | $127K | 24,894 |
| 2026-06-12 | Agarwal Arjun Senior Vice President, Finance | Sale 10b5-1 | −4,340 | $69.85 | $303K | 20,554 |
| 2026-06-12 | Agarwal Arjun Senior Vice President, Finance | Sale 10b5-1 | −3,260 | $70.34 | $229K | 17,294 |
| 2026-06-12 | Agarwal Arjun Senior Vice President, Finance | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −8,000 | 110,000 | ||
| 2026-06-12 | Agarwal Arjun Senior Vice President, Finance | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −1,459 | 62,708 | ||
| 2026-06-12 | Dambkowski Carl Director | Sale 10b5-1 | −12,583 | $70.11 | $882K | 38,743 |
| 2026-06-11 | Dambkowski Carl Director | Sale 10b5-1 | −22,417 | $70.13 | $1.6M | 51,326 |
| 2026-06-02 | Fairmount Funds Management LLC Director | Grant or award · Stock Option (Right to Buy) | +9,136 | 9,136 | ||
| 2026-06-02 | Dambkowski Carl Director | Grant or award · Stock Option (right to buy) | +9,136 | 9,136 | ||
| 2026-06-02 | Kulkarni Samarth Director | Grant or award · Stock Option (right to buy) | +9,136 | 9,136 | ||
| 2026-06-02 | Martin Christopher Nathan Director | Grant or award · Stock Option (right to buy) | +9,136 | 9,136 | ||
| 2026-06-02 | BALL KRISTINE M Director | Grant or award · Stock Option (right to buy) | +9,136 | 9,136 | ||
| 2026-05-21 | Dambkowski Carl Director | Option exercise 10b5-1 | +38,689 | $6.84 | $265K | 155,172 |
| 2026-05-21 | Dambkowski Carl Director | Option exercise 10b5-1 | +11,904 | $7.80 | $93K | 167,076 |
| 2026-05-21 | Dambkowski Carl Director | Option exercise 10b5-1 | +11,667 | $11.77 | $137K | 178,743 |
| 2026-05-21 | Dambkowski Carl Director | Sale 10b5-1 | −38,318 | $58.43 | $2.2M | 140,425 |
| 2026-05-21 | Dambkowski Carl Director | Sale 10b5-1 | −53,447 | $59.10 | $3.2M | 86,978 |
| 2026-05-21 | Dambkowski Carl Director | Sale 10b5-1 | −13,235 | $59.97 | $794K | 73,743 |
| 2026-05-21 | Dambkowski Carl Director | Option exercise · Stock Option (right to buy) 10b5-1 | −38,689 | 32,737 | ||
| 2026-05-21 | Dambkowski Carl Director | Option exercise · Warrant (right to buy) 10b5-1 | −11,904 | 10,952 |
Page 9 of 18 · 346 trades